Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EULAST
2014-002765-30Phase 4Terminated
- Sponsor
- European Group for Research in Schizophrenia
- Start
- Aug 2014
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aripiprazole, paliperidone and paliperidone palmitate in schizophrenia (4 arms), sponsored by European Group for Research in Schizophrenia. Primary endpoint: All-cause discontinuation rate. Started Aug 2014; status: terminated.
02
Drugs
aripiprazolepaliperidonepaliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2014-002765-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002765-30.